Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Li-Ting Liu

Showing results (31-40 of 123) with videos related to

Pageof 13
Sort By:
BMC Cancer|August 11, 2022
Prognostic significance of AKR1C4 and the advantage of combining EBV DNA to stratify patients at high risk of locoregional recurrence of nasopharyngeal carcinomaShan-Shan Guo, Yan-Zhou Chen, Li-Ting Liu, et al.
Frontiers in Oncology|August 28, 2020
Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal CarcinomaXue-Song Sun, Xiao-Hao Wang, Sai-Lan Liu, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 8, 2023
Prognostic value of metastatic cervical lymph node stiffness in nasopharyngeal carcinoma: A prospective cohort studyXue-Song Sun, Jian-Wei Wang, Feng Han, et al.
BMC Cancer|May 12, 2021
Subdivision of de-novo metastatic nasopharyngeal carcinoma based on tumor burden and pretreatment EBV DNA for therapeutic guidance of locoregional radiotherapyJin-Hao Yang, Xue-Song Sun, Bei-Bei Xiao, et al.
Aging|March 30, 2020
Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on plasma Epstein-Barr virus DNA level after induction chemotherapySai-Lan Liu, Xue-Song Sun, Li-Ting Liu, et al.
Medicine|February 5, 2016
Prognostic Value of Plasma Epstein-Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy EraWen-Hui Chen, Lin-Quan Tang, Shan-Shan Guo, et al.
Oral Oncology|February 24, 2023
A new prognostic model for predicting outcomes of patients with recurrent or metastatic nasopharyngeal carcinoma receiving subsequent line (≥2 lines) anti-programmed death-1 monotherapySu-Chen Li, Shen-Wen Deng, Xue-Song Sun, et al.
Oral Oncology|April 17, 2020
Establishment of a prognostic nomogram to identify optimal candidates for local treatment among patients with local recurrent nasopharyngeal carcinomaXue-Song Sun, Yu-Jing Liang, Guo-Dong Jia, et al.
Frontiers in Pharmacology|September 13, 2021
Increased Angiogenin Expression Correlates With Radiation Resistance and Predicts Poor Survival for Patients With Nasopharyngeal CarcinomaShan-Shan Guo, Yu-Jing Liang, Li-Ting Liu, et al.
Therapeutic Advances in Medical Oncology|August 19, 2022
M1 stage subdivisions based on <sup>18</sup>F-FDG PET-CT parameters to identify locoregional radiotherapy for metastatic nasopharyngeal carcinomaHui-Zhi Qiu, Xu Zhang, Sai-Lan Liu, et al.
Pageof 13

Showing results (31-40 of 123) with videos related to

Sort By:
Pageof 13
BMC Cancer|August 11, 2022
Prognostic significance of AKR1C4 and the advantage of combining EBV DNA to stratify patients at high risk of locoregional recurrence of nasopharyngeal carcinomaShan-Shan Guo, Yan-Zhou Chen, Li-Ting Liu, et al.
Frontiers in Oncology|August 28, 2020
Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal CarcinomaXue-Song Sun, Xiao-Hao Wang, Sai-Lan Liu, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 8, 2023
Prognostic value of metastatic cervical lymph node stiffness in nasopharyngeal carcinoma: A prospective cohort studyXue-Song Sun, Jian-Wei Wang, Feng Han, et al.
BMC Cancer|May 12, 2021
Subdivision of de-novo metastatic nasopharyngeal carcinoma based on tumor burden and pretreatment EBV DNA for therapeutic guidance of locoregional radiotherapyJin-Hao Yang, Xue-Song Sun, Bei-Bei Xiao, et al.
Aging|March 30, 2020
Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on plasma Epstein-Barr virus DNA level after induction chemotherapySai-Lan Liu, Xue-Song Sun, Li-Ting Liu, et al.
Medicine|February 5, 2016
Prognostic Value of Plasma Epstein-Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy EraWen-Hui Chen, Lin-Quan Tang, Shan-Shan Guo, et al.
Oral Oncology|February 24, 2023
A new prognostic model for predicting outcomes of patients with recurrent or metastatic nasopharyngeal carcinoma receiving subsequent line (≥2 lines) anti-programmed death-1 monotherapySu-Chen Li, Shen-Wen Deng, Xue-Song Sun, et al.
Oral Oncology|April 17, 2020
Establishment of a prognostic nomogram to identify optimal candidates for local treatment among patients with local recurrent nasopharyngeal carcinomaXue-Song Sun, Yu-Jing Liang, Guo-Dong Jia, et al.
Frontiers in Pharmacology|September 13, 2021
Increased Angiogenin Expression Correlates With Radiation Resistance and Predicts Poor Survival for Patients With Nasopharyngeal CarcinomaShan-Shan Guo, Yu-Jing Liang, Li-Ting Liu, et al.
Therapeutic Advances in Medical Oncology|August 19, 2022
M1 stage subdivisions based on <sup>18</sup>F-FDG PET-CT parameters to identify locoregional radiotherapy for metastatic nasopharyngeal carcinomaHui-Zhi Qiu, Xu Zhang, Sai-Lan Liu, et al.
Pageof 13